Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2015, Article ID 302638, 8 pages
http://dx.doi.org/10.1155/2015/302638
Review Article

Cardiovascular Complications of HIV-Associated Immune Dysfunction

1Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
3Division of Infectious Diseases, Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA

Received 5 November 2014; Accepted 27 December 2014

Academic Editor: H. A. Katus

Copyright © 2015 Akram M. Zaaqoq et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. J. Palella Jr., K. M. Delaney, A. C. Moorman et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators,” The New England Journal of Medicine, vol. 338, pp. 853–860, 1998. View at Google Scholar
  2. J. E. Sackoff, D. B. Hanna, M. R. Pfeiffer, and L. V. Torian, “Causes of death among persons with aids in the era of highly active antiretroviral therapy: New York City,” Annals of Internal Medicine, vol. 145, no. 6, pp. 397–406, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. F. J. Palella Jr., R. K. Baker, A. C. Moorman et al., “Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 1, pp. 27–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. K. Grinspoon, C. Grunfeld, D. P. Kotler et al., “State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary,” Circulation, vol. 118, no. 2, pp. 198–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. Currier, A. Taylor, F. Boyd et al., “Coronary heart disease in HIV-infected individuals,” Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 4, pp. 506–512, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. V. A. Triant, H. Lee, C. Hadigan, and S. K. Grinspoon, “Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 7, pp. 2506–2512, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. O. Galescu, A. Bhangoo, and S. Ten, “Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS,” Reviews in Endocrine and Metabolic Disorders, vol. 14, no. 2, pp. 133–140, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Aberg, “Aging, inflammation, and HIV infection,” Topics in Antiviral Medicine, vol. 20, no. 3, pp. 101–105, 2012. View at Google Scholar · View at Scopus
  9. “UNAIDS report on the global AIDS epidemic 2013,” 2013.
  10. WHO, Global Update on HIV Treatment 2013: Results, Impact and Opportunities. WHO Report in Partnership with UNICEF and UNAIDS, WHO, 2013.
  11. M. G. Law, N. Friis-Møller, W. M. El-Sadr et al., “The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study,” HIV Medicine, vol. 7, no. 4, pp. 218–230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Santos, R. Palacios, M. González, J. Ruiz, and M. Márquez, “Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar study),” International Journal of STD & AIDS, vol. 16, no. 10, pp. 677–680, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. R. B. Effros, C. V. Fletcher, K. Gebo et al., “Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions,” Clinical Infectious Diseases, vol. 47, no. 4, pp. 542–553, 2008. View at Publisher · View at Google Scholar
  14. V. A. Triant, H. Lee, C. Hadigan, and S. K. Grinspoon, “Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2506–2512, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. “Cigarette smoking among adults—United States, 2006,” Morbidity and Mortality Weekly Report, vol. 56, pp. 1157–1161, 2006.
  16. K. K. Browning, M. E. Wewers, A. K. Ferketich, and P. Diaz, “Tobacco use and cessation in HIV-infected individuals,” Clinics in Chest Medicine, vol. 34, no. 2, pp. 181–190, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Tesoriero, S. M. Gieryic, A. Carrascal, and H. E. Lavigne, “Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation,” AIDS and Behavior, vol. 14, no. 4, pp. 824–835, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. R. Lifson, J. Neuhaus, J. R. Arribas, M. D. van Berg-Wolf, A. M. Labriola, and T. R. H. Read, “Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial,” The American Journal of Public Health, vol. 100, no. 10, pp. 1896–1903, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. R. Loonam and A. Mullen, “Nutrition and the HIV-Associated lipodystrophy syndrome,” Nutrition Research Reviews, vol. 25, no. 2, pp. 267–287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Samaras, H. Wand, M. Law, S. Emery, D. Cooper, and A. Carr, “Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia,” Diabetes Care, vol. 30, pp. 113–119, 2007. View at Google Scholar
  21. A. P. Kengne, Z. June-Rose Mchiza, A. G. B. Amoah, and J. C. Mbanya, “Cardiovascular diseases and diabetes as economic and developmental challenges in Africa,” Progress in Cardiovascular Diseases, vol. 56, no. 3, pp. 302–313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Arie, “HIV infection is rising among over 50s across the world, figures show,” British Medical Journal, vol. 341, Article ID c4064, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Kirigia, H. B. Sambo, L. G. Sambo, and S. P. Barry, “Economic burden of diabetes mellitus in the WHO African region,” BMC International Health and Human Rights, vol. 9, article 6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. K. Hansson, “Inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1626–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. L. H. Kuller, R. Tracy, W. Belloso et al., “Inflammatory and coagulation biomarkers and mortality in patients with HIV infection,” PLoS Medicine, vol. 5, no. 10, article e203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Grunfeld, J. A. Delaney, C. Wanke et al., “Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study,” AIDS, vol. 23, no. 14, pp. 1841–1849, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Klein, L. B. Hurley, C. P. Quesenberry Jr., and S. Sidney, “Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?” Journal of Acquired Immune Deficiency Syndromes, vol. 30, no. 5, pp. 471–477, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Friis-Møller, P. Reiss, C. A. Sabin et al., “Class of antiretroviral drugs and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 356, no. 17, pp. 1723–1735, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. K. A. Lichtenstein, C. Armon, K. Buchacz et al., “Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study,” Clinical Infectious Diseases, vol. 51, no. 4, pp. 435–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Mocroft, A. N. Phillips, J. Gatell et al., “Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study,” The Lancet, vol. 370, no. 9585, pp. 407–413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. C. F. Kelley, C. M. R. Kitchen, P. W. Hunt et al., “Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment,” Clinical Infectious Diseases, vol. 48, no. 6, pp. 787–794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Danesh, S. Kaptoge, A. G. Mann et al., “Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review,” PLoS Medicine, vol. 5, no. 4, article e78, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Madden, G. Lee, D. P. Kotler et al., “Association of antiretroviral therapy with fibrinogen levels in HIV-infection,” AIDS, vol. 22, no. 6, pp. 707–715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Maldarelli, S. Palmer, M. S. King et al., “ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia,” PLoS Pathogens, vol. 3, no. 4, article e46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J Buzón, M. Massanella, J. M. Llibre et al., “HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects,” Nature Medicine, vol. 16, no. 4, pp. 460–465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. R. S. Veazey, M. DeMaria, L. V. Chalifoux et al., “Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection,” Science, vol. 280, no. 5362, pp. 427–431, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. Q. Li, J. D. Estes, L. Duan et al., “Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection,” The Journal of Infectious Diseases, vol. 197, no. 3, pp. 420–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Cassol, S. Malfeld, P. Mahasha et al., “Persistent microbial translocation and immune activation in HIV-1-infected south africans receiving combination antiretroviral therapy,” Journal of Infectious Diseases, vol. 202, no. 5, pp. 723–733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. A. W. Sylwester, B. L. Mitchell, J. B. Edgar et al., “Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects,” The Journal of Experimental Medicine, vol. 202, no. 5, pp. 673–685, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. D. M. Naeger, J. N. Martin, E. Sinclair et al., “Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease,” PLoS ONE, vol. 5, no. 1, Article ID e8886, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. E. Lipshultz, E. J. Orav, S. P. Sanders, and S. D. Colan, “Immunoglobulins and left ventricular structure and function in pediatric HIV infection,” Circulation, vol. 92, no. 8, pp. 2220–2225, 1995. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Achiron, R. Margalit, R. Hershkoviz et al., “Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease: upregulation of T cell proliferation and downregulation of tumor necrosis factor α secretion,” Journal of Clinical Investigation, vol. 93, no. 2, pp. 600–605, 1994. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Friis-Moller, C. A. Sabin, R. Weber et al., “Combination antiretroviral therapy and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 349, pp. 1993–2003, 2003. View at Google Scholar
  44. S. D. Holmberg, A. C. Moorman, J. M. Williamson et al., “Protease inhibitors and cardiovascular outcomes in patients with HIV-1,” The Lancet, vol. 360, no. 9347, pp. 1747–1748, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. M. L. de Saint, O. Vandhuick, P. Guillo et al., “Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study),” Atherosclerosis, vol. 185, no. 2, pp. 361–367, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. The SMART/INSIGHT and the D:A:D Study Groups, “Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients,” Aids, vol. 22, no. 14, pp. F17–F24, 2008. View at Publisher · View at Google Scholar
  47. S. Lang, M. Mary-Krause, L. Cotte et al., “Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French hospital database on HIV ANRS cohort CO4,” Archives of Internal Medicine, vol. 170, no. 14, pp. 1228–1238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. C. A. Sabin, S. W. Worm, R. Weber et al., “Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration,” The Lancet, vol. 371, no. 9622, pp. 1417–1426, 2008. View at Google Scholar
  49. T. Antoniou, J. Gillis, M. R. Loutfy et al., “Impact of the data collection on adverse events of Anti-HIV drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada,” Journal of the International Association of Providers of AIDS Care, vol. 13, no. 2, pp. 153–159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Dellamonica, C. Katlama, L. Lévy-Bachelot, J.-P. Daures, and L. Finkielsztejn, “Abacavir (Ziagen) use between 2003 and 2008 in France according to the electronic medical record NADIS,” Medecine et Maladies Infectieuses, vol. 43, no. 11-12, pp. 467–474, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. E. S. Brouwer, S. Napravnik, J. J. Eron Jr. et al., “Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients,” Epidemiology, vol. 25, no. 3, pp. 406–417, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Smith, C. A. Sabin, J. D. Lundgren et al., “Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study,” AIDS, vol. 24, no. 10, pp. 1537–1548, 2010. View at Publisher · View at Google Scholar
  53. C. H. Brothers, J. E. Hernandez, A. G. Cutrell et al., “Risk of myocardial infarction and abacavir therapy: No increased risk across 52 glaxosmithkline-sponsored clinical trials in adult subjects,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 1, pp. 20–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. H. J. Ribaudo, C. A. Benson, Y. Zheng et al., “No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT,” Clinical Infectious Diseases, vol. 52, no. 7, pp. 929–940, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. X. Ding, E. Andraca-Carrera, C. Cooper et al., “No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis,” Journal of Acquired Immune Deficiency Syndromes, vol. 61, no. 4, pp. 441–447, 2012. View at Google Scholar
  56. I. J. MacLeod, C. F. Rowley, S. Lockman et al., “Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women,” Journal of the International AIDS Society, vol. 15, no. 2, Article ID 17393, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. B. M. Bergersen, S. Tonstad, L. Sandvik, and J. N. Bruun, “Low prevalence of high-density lipoprotein cholesterol level < 1 mmol/L in non-nucleoside reverse transcriptase inhibitor recipients,” International Journal of STD & AIDS, vol. 16, no. 5, pp. 365–369, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Canning, “The economics of HIV/AIDS in low-income countries: the case for prevention,” Journal of Economic Perspectives, vol. 20, no. 3, pp. 121–142, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. S. D. Fisher, B. S. Kanda, T. L. Miller, and S. E. Lipshultz, “Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients,” American Journal of Cardiovascular Drugs, vol. 11, no. 6, pp. 383–394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Friis-Møller, R. Thiébaut, P. Reiss et al., “Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 17, no. 5, pp. 491–501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Y. Hsue, K. Squires, A. F. Bolger et al., “Screening and assessment of coronary heart disease in HIV-infected patients,” Circulation, vol. 118, no. 2, pp. e41–e47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. Gibbons R. J., G. J. Balady, J. T. Bricker et al., “ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines),” Journal of the American College of Cardiology, vol. 40, no. 8, pp. 1531–1540, 2002. View at Google Scholar
  63. N. J. Stone, J. G. Robinson, A. H. Lichtenstein et al., “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines,” Circulation, vol. 129, pp. S1–S45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. S. C. Smith Jr. and S. M. Grundy, “2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol,” Journal of the American College of Cardiology, vol. 64, no. 6, pp. 601–612, 2014. View at Publisher · View at Google Scholar
  65. M. Schambelan, C. A. Benson, A. Carr et al., “Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel,” Journal of Acquired Immune Deficiency Syndromes, vol. 31, no. 3, pp. 257–275, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. M. P. Dubé, “Will statins be an effective anti-inflammatory intervention for prevention of cardiovascular disease in patients with HIV?” Journal of Infectious Diseases, vol. 209, no. 8, pp. 1149–1150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2195–2207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. J. H. Stein, C. M. Hadigan, T. T. Brown et al., “Prevention strategies for cardiovascular disease in HIV-infected patients,” Circulation, vol. 118, no. 2, pp. e54–e60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report,” Evidence-Based Eye Care, vol. 4, no. 3, pp. 179–180, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. R. C. Kaplan, L. A. Kingsley, A. R. Sharrett et al., “Ten-year predicted coronary heart disease risk in HIV-infected men and women,” Clinical Infectious Diseases, vol. 45, no. 8, pp. 1074–1081, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Hadigan, “Diabetes, insulin resistance, and HIV,” Current Infectious Disease Reports, vol. 8, no. 1, pp. 69–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Gavrila, S. Tsiodras, J. Doweiko et al., “Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus—positive subjects: a cross-sectional study,” Clinical Infectious Diseases, vol. 36, no. 12, pp. 1593–1601, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Doll, R. Peto, J. Boreham, and I. Sutherland, “Mortality in relation to smoking: 50 Years' observations on male British doctors,” British Medical Journal, vol. 328, no. 7455, pp. 1519–1528, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Petoumenos, S. Worm, P. Reiss et al., “Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study,” HIV Medicine, vol. 12, no. 7, pp. 412–421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. G. L. Humfleet, K. Delucchi, K. Kelley, S. M. Hall, J. Dilley, and G. Harrison, “Characteristics of HIV-positive cigarette smokers: a sample of smokers facing multiple challenges,” AIDS Education and Prevention, vol. 21, no. 3, pp. 54–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. D. J. Vidrine, R. C. Arduino, and E. R. Gritz, “The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV/AIDS,” AIDS Patient Care and STDs, vol. 21, no. 9, pp. 659–666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. D. J. Vidrine, R. M. Marks, R. C. Arduino, and E. R. Gritz, “Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes,” Nicotine & Tobacco Research, vol. 14, no. 1, pp. 106–110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. A. B. Lazev, D. J. Vidrine, R. C. Arduino, and E. R. Gritz, “Increasing access to smoking cessation treatment in a low-income, HIV-positive population: the feasibility of using cellular telephones,” Nicotine and Tobacco Research, vol. 6, no. 2, pp. 281–286, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. J. E. Burkhalter, C. M. Springer, R. Chhabra, J. S. Ostroff, and B. D. Rapkin, “Tobacco use and readiness to quit smoking in low-income HIV-infected persons,” Nicotine and Tobacco Research, vol. 7, no. 4, pp. 511–522, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. D. J. Vidrine, R. C. Arduino, and E. R. Gritz, “Impact of a cell phone intervention on mediating mechanisms of smoking cessation in individuals living with HIV/AIDS,” Nicotine and Tobacco Research, vol. 8, no. supplement 1, pp. S103–S108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Y. Park-Wyllie and T. Antoniou, “Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series,” AIDS, vol. 17, no. 4, pp. 638–640, 2003. View at Publisher · View at Google Scholar · View at Scopus